NASDAQ : ELTX
Elicio Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 1.69 USD (Oct 30, 2026, 3:05 PM EDT) · Market cap 44.42M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 42.58M |
| Enterprise Value | 33.24M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 26.28M |
| Shares Outstanding | 26.28M |
| Shares Change (YoY) | +23.82% |
| Shares Change (QoQ) | +5.67% |
| Owned by Insiders (%) | 21.57% |
| Owned by Institutions (%) | 21.03% |
| Float | 19.20M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 4.64 |
| P/TBV Ratio | 5.56 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.77 |
| Quick Ratio | 2.55 |
| Debt / Equity | 1.78 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -24.00 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -774.56% |
| Return on Assets (ROA) | -77.88% |
| Return on Invested Capital (ROIC) | -122.09% |
| Return on Capital Employed (ROCE) | -171.36% |
| Weighted Average Cost of Capital (WACC) | 13.60% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.15M |
| Employee Count | 33 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.98 |
| 52-Week Price Change | -83.10% |
| 50-Day Moving Average | 2.03 |
| 200-Day Moving Average | 6.75 |
| Relative Strength Index (RSI) | 37.30 |
| Average Volume (20 Days) | 272,440 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 1.70M |
| Short Previous Month | 1.55M |
| Short % of Shares Out | 6.48% |
| Short % of Float | 8.87% |
| Short Ratio (days to cover) | 5.50 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -37.92M |
| Pretax Income | -37.84M |
| Net Income | -37.84M |
| EBITDA | -37.74M |
| EBIT | -37.92M |
| Earnings Per Share (EPS) | -$2.17 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 23.48M |
| Total Debt | 14.15M |
| Net Cash | 9.33M |
| Net Cash Per Share | $0.36 |
| Equity (Book Value) | 7.94M |
| Book Value Per Share | 0.36 |
| Working Capital | 16.28M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -37.69M |
| Capital Expenditures | -16,000 |
| Depreciation & Amortization | 180,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -37.71M |
| FCF Per Share | -$1.43 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -23.82% |
| Shareholder Yield | -23.82% |
| Earnings Yield | -134.08% |
| FCF Yield | -85.40% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $13.67 |
| Price Target Difference | 743.83% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |